Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps. This segment also provides veterinary imaging instruments and services, such as digital radiography solutions and ultrasound systems, as well as sells mobile digital radiography products; Cloudbank, a Web-based image storage solution; ViewCloud, a picture archival and communications system for Cloudbank; point-of-care heartworm diagnostic test products for dogs and cats; TRI-HEART Plus chewable tablets for the treatment of canine heartworm infection, and treatment and control of ascarid and hookworm infections; and allergy products and services, including ALLERCEPT definitive allergen panels, and therapy shots or drops. Its Other Vaccines, Pharmaceuticals and Products segment offers bovine vaccines primarily under the Titanium and MasterGuard brands; biological and pharmaceutical products for other animal health companies; and turnkey services comprising research, licensing, production, labeling, and packaging. The company sells its products to veterinarians through a field organization and third-party distributors; and trade shows, print advertising, and other distribution relationships. Heska Corporation has product development partnership and licensing agreement with MBio Diagnostics, Inc. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation. Heska Corporation was founded in 1988 and is headquartered in Loveland, Colorado.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:HSKA
CUSIPN/A
Phone970-493-7272
Debt
Debt-to-Equity RatioN/A
Current Ratio3.17
Quick Ratio1.70
Price-To-Earnings
Trailing P/E Ratio48.41
Forward P/E Ratio60.00
P/E GrowthN/A
Sales & Book Value
Annual Sales$129.34 million
Price / Sales5.81
Cash Flow$2.9111 per share
Price / Cash34.42
Book Value$13.87 per share
Price / Book7.22
Profitability
EPS (Most Recent Fiscal Year)$2.07
Net Income$9.95 million
Net Margins4.67%
Return on Equity11.49%
Return on Assets8.75%
Miscellaneous
Employees345
Outstanding Shares7,500,000
Market Cap$734.03 million
Heska (NASDAQ:HSKA) Frequently Asked Questions
What is Heska's stock symbol?
Heska trades on the NASDAQ under the ticker symbol "HSKA."
How were Heska's earnings last quarter?
Heska Corp (NASDAQ:HSKA) announced its quarterly earnings results on Tuesday, August, 7th. The medical research company reported $0.24 EPS for the quarter, beating the consensus estimate of $0.17 by $0.07. The medical research company had revenue of $29.66 million for the quarter, compared to the consensus estimate of $30.19 million. Heska had a return on equity of 11.49% and a net margin of 4.67%. View Heska's Earnings History.
When is Heska's next earnings date?
What price target have analysts set for HSKA?
6 brokers have issued 12 month price objectives for Heska's stock. Their forecasts range from $93.00 to $123.00. On average, they expect Heska's share price to reach $107.50 in the next twelve months. This suggests a possible upside of 7.3% from the stock's current price. View Analyst Price Targets for Heska.
What is the consensus analysts' recommendation for Heska?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heska in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Heska.
What are Wall Street analysts saying about Heska stock?
Here are some recent quotes from research analysts about Heska stock:
- 1. According to Zacks Investment Research, "Heska Corporation sells advanced veterinary diagnostic and specialty products. Heska's state-of-the-art offerings include blood testing instruments and supplies, digital imaging products, software and services, data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. The Company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled support to veterinarians. " (8/9/2018)
- 2. B. Riley analysts commented, "We expect Q3 results to be generally in line. We forecast revenue of $35.8 million and EPS of $0.40 versus consensus of $36.0 million and EPS of $0.41. We model revenue growth at 7.1%, reflecting ongoing momentum in core blood diagnostics within its Core Companion Animal Health offset by Other Vaccines, Pharmaceuticals and Products segment which pulled forward revenue last quarter (but expecting to finish off Q4 strong)." (10/27/2017)
Who are some of Heska's key competitors?
Some companies that are related to Heska include Aerie Pharmaceuticals (AERI), argenx (ARGX), Halozyme Therapeutics (HALO), Crispr Therapeutics (CRSP), Spark Therapeutics (ONCE), Acceleron Pharma (XLRN), Regenxbio (RGNX), Repligen (RGEN), Momenta Pharmaceuticals (MNTA), Rubius Therapeutics (RUBY), Atara Biotherapeutics (ATRA), Sangamo Therapeutics (SGMO), Denali Therapeutics (DNLI), Editas Medicine (EDIT) and Iovance Biotherapeutics (IOVA).
Who are Heska's key executives?
Heska's management team includes the folowing people:
- Mr. Kevin S. Wilson, CEO, Pres & Director (Age 46)
- Mr. Jason A. Napolitano, COO, Chief Strategist & Sec. (Age 50)
- Ms. Catherine Grassman CPA, VP, Chief Accounting Officer & Corp. Controller (Age 42)
- Mr. Steven M. Eyl, Exec. VP of Global Sales & Marketing (Age 52)
- Dr. Nancy Wisnewski, Exec. VP of Diagnostic Operations & Product Devel. (Age 55)
Has Heska been receiving favorable news coverage?
News stories about HSKA stock have trended somewhat positive recently, according to Accern Sentiment. Accern identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Heska earned a media and rumor sentiment score of 0.07 on Accern's scale. They also gave news articles about the medical research company an impact score of 44.81 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for Heska.
Who are Heska's major shareholders?
Heska's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (13.78%), FMR LLC (6.16%), Riverbridge Partners LLC (5.15%), Redmile Group LLC (4.73%), Fred Alger Management Inc. (3.72%) and Standard Life Aberdeen plc (3.42%). Company insiders that own Heska stock include Bonnie J Trowbridge, Carol Wrenn, G Irwin Gordon, Jason A Napolitano, John Mcmahon, Kevin S Wilson, Michael J Mcginley, Nancy Wisnewski, Rod Lippincott, Sharon J Larson, Steve Asakowicz and Steven M Eyl. View Institutional Ownership Trends for Heska.
Which institutional investors are selling Heska stock?
HSKA stock was sold by a variety of institutional investors in the last quarter, including Bank of New York Mellon Corp, Standard Life Aberdeen plc, Tygh Capital Management Inc., Grandeur Peak Global Advisors LLC, Grace & White Inc. NY, GSA Capital Partners LLP, KBC Group NV and NJ State Employees Deferred Compensation Plan. Company insiders that have sold Heska company stock in the last year include Bonnie J Trowbridge, G Irwin Gordon, Jason A Napolitano, John Mcmahon, Michael J Mcginley, Nancy Wisnewski and Steven M Eyl. View Insider Buying and Selling for Heska.
Which institutional investors are buying Heska stock?
HSKA stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, Fred Alger Management Inc., Redmile Group LLC, BlackRock Inc., Raymond James & Associates, Janus Henderson Group PLC, Dimensional Fund Advisors LP and Summit Creek Advisors LLC. View Insider Buying and Selling for Heska.
How do I buy shares of Heska?
Shares of HSKA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Heska's stock price today?
One share of HSKA stock can currently be purchased for approximately $100.20.
How big of a company is Heska?
Heska has a market capitalization of $734.03 million and generates $129.34 million in revenue each year. The medical research company earns $9.95 million in net income (profit) each year or $2.07 on an earnings per share basis. Heska employs 345 workers across the globe.
How can I contact Heska?
Heska's mailing address is 3760 ROCKY MOUNTAIN AVENUE, LOVELAND CO, 80538. The medical research company can be reached via phone at 970-493-7272 or via email at [email protected]
MarketBeat Community Rating for Heska (NASDAQ HSKA)
MarketBeat's community ratings are surveys of what our community members think about Heska and other stocks. Vote "Outperform" if you believe HSKA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HSKA will underperform the S&P 500 over the long term. You may vote once every thirty days.
